Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy-Reference-Cited by-同舟云学术

Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy

Published:2013-12 Issue:6 Volume:1 Page:480-487
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Shimada Yuichi J.,Passeri Jonathan J.,Baggish Aaron L.,O'Callaghan Caitlin,Lowry Patricia A.,Yannekis Gia,Abbara Suhny,Ghoshhajra Brian B.,Rothman Richard D.,Ho Carolyn Y.,Januzzi James L.,Seidman Christine E.,Fifer Michael A.

Funder

National Institutes of Health

Roche, Critical Diagnostics, BG Medicine, Siemens, Singulex, Novartis, Amgen, Zensun, and Thermo Fisher Scientific

National Institutes of Health and the Howard Hughes Medical Institute

Merck & Co., Inc

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference27 articles.

1. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles;Maron;JAMA,1996

2. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease;Varnava;Heart,2000

3. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy;Elliott;Lancet,2001

4. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy;Olivotto;J Am Coll Cardiol,2003

5. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy;Green;J Am Coll Cardiol Img,2012

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Drug Therapy Efficacy in Patients With Hypertrophic Cardiomyopathy: A Network Meta-Analysis;The American Journal of Cardiology;2024-09

2. Discontinuation of afterload-reducing drugs decreases left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy;Frontiers in Cardiovascular Medicine;2024-07-16

3. Corneal fibrosis: From in vitro models to current and upcoming drug and gene medicines;Advanced Drug Delivery Reviews;2024-06

4. Sacubitril/valsartan for the treatment of non‐obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM);European Journal of Heart Failure;2024-05-27

5. Targeting Interactions between Fibroblasts and Macrophages to Treat Cardiac Fibrosis;Cells;2024-04-30